Trial results supported recent FDA approval for patients with relapsed/refractory disease HOUSTON ― Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel anti-CD19 chimeric antigen receptor (CAR) T cell therapy, obecabtagene autoleucel (obe-cel), experienced high […]
City of Houston Live
City of Katy katy
This player embeds official streams. If the live feed is offline, use the source link to view updates.
Browse previous videos
